Digital Pathology AI
P

PictorLabs

PictorLabs, which now styles its name Pictor Labs, makes software that stains tissue images with AI instead of chemicals, and a tissue intelligence platform built on it. Drug companies, contract research organizations, diagnostic developers and academic labs use it so one tissue section can yield several stains, saving tissue and reagents for other tests.

It sells four staining products. ClearStain makes a virtual H&E stain from an unstained section, leaving the tissue free for sequencing. DeepStain makes several stains from one scan of unstained tissue. ReStain turns existing H&E slides into special stains and IHC like markers, and RetroStain converts stains between scanners and imaging methods. The Tissue Intelligence Platform turns an archived H&E slide into a virtual stain panel, fuses it with clinical, molecular and treatment data, and returns a research score explained by named tissue features.

Everything is sold for research, such as drug development and preclinical safety studies, and nothing is cleared for diagnosis. The software runs on an appliance inside the customer's network or in a cloud that Pictor Labs manages.

PictorLabs is a Los Angeles company built on its cofounders' published research. It raised a $30 million Series B in 2024 and extended it with a strategic investment from Labcorp in 2025. No price is published.

AI Health Index verifiedNovember 8, 2026
Compare PictorLabs with other vendors
Founded
—
Headquarters
Los Angeles, California, United States
Categories
pathology-ai, drug-discovery
Indexed Products
ClearStain, DeepStain, ReStain, RetroStain, Tissue Intelligence Platform
Buyer Segments
Biopharma research and development, Contract research organizations and preclinical safety teams, Academic medical centers and research laboratories, Pathology laboratories (research use)
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
AA on AI CentralityThe artificial intelligence is the product. Remove the model and there is nothing left to sell.
Vendor Published

The models are the product. Every PictorLabs product returns an image that a deep learning model generates: a virtual H&E from an unstained section, several virtual stains from one autofluorescence scan, virtual special stains from an existing H&E slide, or a stain converted between scanners and imaging methods. PictorLabs sells no scanner, stain or laboratory service. Without the models there is nothing to deliver.

CC on Autonomy and Oversight ModelAutonomy is claimed and oversight is asserted without a mechanism. Human in the loop appears as a phrase rather than a described control.
Vendor Published

Pathologist review is asserted, and checking each output is left to the user. PictorLabs's FAQ and Safe AI page say virtual staining is adjunctive, does not interpret findings or assign diagnoses, and that outputs are reviewed by qualified pathologists and not accepted autonomously. Its terms say it makes no representations about the accuracy of AI generated outputs, and that users rely on them at their own risk and must verify them. Every product carries a research use only label.

The Tissue Intelligence Platform returns the share of tiles in each named tissue state behind a score, so a scientist can see what produced it. Nothing describes how a customer checks a delivered virtual stain against a chemical one or when a stain is not to be relied on.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

The approach is published in method papers, without product versions or update practice. PictorLabs's products rest on supervised deep learning its founders published, trained on co registered image pairs from the same tissue section. They turn label free autofluorescence or brightfield images, or chemically stained sections, into other stains, and the Tissue Intelligence Platform fuses virtual stains with clinical, molecular and treatment data into a score explained by named tissue states.

The models behind each product are not named or versioned, and their training data is not described beyond curated image pairs. No release notes or change notices are published.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

PictorLabs builds its own staining models from methods its founders published, and no outside model provider is named or implied. The on premises appliance keeps images in the customer's environment, and Pictor Labs supplies the software and updates.

For the cloud option, which Pictor Labs manages, no hosting provider, region or subprocessor list is published. The privacy policy says personal information is shared with service providers without naming them.

BB on Clinical and Operational EvidenceNamed deployments with dated outcome figures and enough method to test them, or published research short of independent validation.
Peer Reviewed Publication

Peer reviewed research led by the founders supports the method, without independent validation of the products sold. A 2019 paper in Nature Biomedical Engineering turned autofluorescence scans of unstained tissue into H&E, Jones and Masson's trichrome stains across several organs, with blinded review by board certified pathologists. A 2020 paper in Light: Science and Applications applied several stains to different structures in one label free section, and a 2021 paper in Nature Communications turned H&E kidney biopsies into virtual special stains for kidney disease other than cancer.

Later papers cover label free HER2 staining of breast tissue (2022) and virtual H&E in lymphoma (Journal of Hematopathology and International Journal of Surgical Pathology, 2024). Conference work includes a 2024 comparison of virtual and chemical H&E for lymphoma diagnosis with Johns Hopkins, UCLA and the University of Maryland, a 2026 AACR abstract on a virtual stromal stain as a prognostic readout in pancreatic cancer, and a neurotoxicity study with Charles River. The home page reports 1,360 diagnostic slides from public research datasets processed by a model not trained on them, across seven cancer types.

The evidence page lists these studies without figures. The papers do not name product versions, and none is an independent evaluation of ClearStain, DeepStain, ReStain, RetroStain or the Tissue Intelligence Platform as sold.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

Privacy assurances are general, with retention and training use left to contracts. The company displays SOC and CCPA compliance marks, and its on premises appliance keeps input images and generated stains inside the customer's network. For the cloud option, its deployment page says data retention, storage location and encryption standards are defined by the agreed service policy.

Nothing published says whether customer images train or refine its staining models, beyond training on curated, co registered image pairs, or how training tissue was sourced and de identified. Its privacy policy (last updated 8 June 2026) covers account and website data and allows de identified or aggregated data to be shared with third parties. No safety engineering for the models is published, such as how a virtual stain that invents or misses structure is caught.

Regulatory and Compliance
CC on HIPAA and BAA PostureA status is stated but not supported: compliance is claimed, or business associate status stated, without the underlying document, including where the only privacy notice published covers the website rather than the service that handles patients. The mirror case grades here as well: a substantive privacy document that reaches the service, with no statement of business associate status anywhere and no scope position taken. One of the two elements the band above asks for is present, which is a grade below it and not a grade at the floor.
Vendor Published

The privacy policy reaches people who hold accounts with the service, and takes no position on patient data. The policy, effective June 2026, covers website visitors, account holders, event participants and business partners. It says aggregated or de identified data may be shared with third parties.

It does not address tissue images or any patient information in them, and no business associate status, scope position or agreement is published. The products are sold for research, where images are often de identified, but nothing published says so.

BB on Security Certifications and Trust CenterA recognized certification is named in the vendor own material without the artifact, or with a scope or renewal question the buyer has to raise. A recognized certification here is an audit of how the vendor operates security, such as SOC 2, HITRUST or ISO/IEC 27001. A certification has a scope and a clock, and both are part of this grade. A certification the vendor attaches to its data center, hosting facility or cloud provider, rather than presenting as its own, is the host's and does not count here.
Vendor Published

PictorLabs displays a SOC compliance mark, without the report type, scope or date. Its site carries an AICPA SOC mark and a CCPA compliance mark in the footer. The AICPA mark indicates an audit of controls by an independent accountant.

PictorLabs does not say whether it is a SOC 2 report, whether it is Type I or Type II, what it covers or when it was issued. No trust center or penetration testing statement is published.

CC on FDA and Regulatory StatusNo device claim is made and the product is scoped accordingly. Most administrative and operational products sit here and are not penalized for it, because this axis grades the appropriateness of the positioning rather than possession of a clearance. A stated limit on use, such as research use only or a clause that the product gives no medical advice, beside marketing that sells the product for clinical decisions also sits here, with both quoted, because the buyer has to ask which one governs.
Vendor Published

PictorLabs makes no device claim, and its products are labeled for research. Each product carries a research use only, not for use in diagnostic procedures label. Its evidence page says its virtual staining is not cleared or approved for clinical diagnostic use, and its terms say the technology is not approved by the FDA for clinical use. The FDA's databases list no PictorLabs device.

Its published research includes diagnostic comparisons in lymphoma and HER2 breast tissue. These describe where the method could go, not what is sold today.

BB on AI Governance and Bias DisclosureA governance framework with named process behind it, such as certification to an artificial intelligence management standard, or material written for a customer own review committee to evaluate the product with. A framework covering the vendor whole portfolio counts when its scope reaches this product; what it cannot supply is the product specific evaluation the band above asks for. Published results within the one group where the performance of this product is most at risk also sit here: evaluation on the question this axis asks, short of the comparison across groups the band above requires. A medical device clearance or certification, and the quality system behind it, does not reach this band on its own; it is graded under regulatory status. A regulator reviewed plan governing how the model may change does reach it.
Vendor Published

A named evaluation process is published, without results compared across tissues, scanners or laboratories. PictorLabs's Safe AI page sets out how virtual stains are evaluated, with image metrics such as PSNR and SSIM during development and release criteria that rest on blinded review by board certified pathologists. The review scores nuclear clarity, structural and cytoplasmic detail, overall staining effectiveness and sharpness, and diagnostic concordance studies are run for evaluation only.

The pages publish no results by tissue type, scanner, laboratory or staining protocol, and no monitoring after release is described. RetroStain is offered to even out color across scanners, and the 2019 paper is described as validated across organs and stain types.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

Responsibility for outputs sits with the user. PictorLabs's terms say it makes no representations about the accuracy of AI generated outputs, that users rely on them at their own risk and must verify them, and that disputes go to arbitration.

A virtual stain can be checked against a chemical stain of the same tissue, which is how the published studies were run. But no error rate for a product as sold, warranty, reprocessing commitment or indemnity is published.

Integration and Deployment
CC on EHR and Interoperability DepthIntegration is claimed through standards or a middleware layer with no system named and nothing to verify.
Vendor Published

No clinical record integration exists, and research system integration is described in general terms. The on premises option connects over the network to a scanner or image management system, and the cloud option takes images by manual upload or an API.

Its home page shows Grundium, Hamamatsu, Proscia, Pramana, PredxBio, Inova and the University of Maryland Medical Center among its collaborators, without saying what each integration does or whether it is in production. No named image management system integration, file format or interface specification is documented.

BB on Deployment Model and Data ResidencyOptions and residency are stated with isolation or the processing path left open.
Vendor Published

Two deployment models are documented, with residency stated for the on premises option and left to contract for the cloud. The on premises option is an appliance or GPU workstation inside the customer's network, needs no internet for processing, and keeps input images, intermediate outputs and generated stains within local storage, with no image data leaving the customer environment.

The cloud option runs in a cloud Pictor Labs manages, with storage in that cloud, a customer managed cloud or a local environment, and retention, storage location and encryption set by the agreed service policy. No cloud provider, region or tenant isolation is published.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

No price is published, but the outline of how the products are sold can be worked out. PictorLabs describes four staining products and a Tissue Intelligence Platform for research use, run on an appliance in the customer's network or in a cloud it manages. A biomarker menu is available on request, and access starts with a demo request or a review of one of the customer's own cohorts.

Nothing published says whether customers pay per slide, per stain, per study or by license, or what an on premises deployment costs.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

The stain menu and settings are spelled out, with peer reviewed validation behind part of them. The products cover virtual H&E, special stains such as Masson's trichrome, Jones and PAS, and IHC like markers such as PanCK, CD45, CD8, Ki67 and p53, with more on a biomarker menu on request. Inputs include brightfield, autofluorescence, H&E, immunohistochemistry and multiplex immunofluorescence images. Published work covers several organs, kidney biopsies, breast tissue for HER2, lymphoma and pancreatic cancer, and the home page reports seven cancer types evaluated.

PictorLabs names clinical development, diagnostic development, biomarker strategy, translational research and preclinical toxicology among its uses, with a neurotoxicity study run with Charles River. All use is research only, and validation for markers on the request menu is not published.

Tracked Since Listing

Product updates

Material product, regulatory, evidence and commercial changes at PictorLabs, each verified against a live source and tagged to the capability axis it bears on. Funding rounds and awards are not product changes and are not logged.

Oct 26, 2026Product / capabilityPartially verified

Pictor Labs introduced its Tissue Intelligence Platform, which takes a single H&E whole slide image, generates virtual stains such as CD8, Ki67, p53 and trichrome, and combines them with clinical, molecular and treatment data into a tissue score linked to research outcomes. Each case shows the share of tissue in named states, so scientists can see what drove the score.

Bears on: AI CentralitySource
Our read on this update →Tracked since Oct 2026
Alternatives

Alternatives to PictorLabs

Other products that do the same kind of work as PictorLabs, and what each one does.

All PictorLabs alternatives, with prices →

Tissue intelligence company for drug development, applying computer vision and machine learning to H&E, immunohistochemistry, multiplex imaging and spatial transcriptomics and linking tissue features to clinical outcomes.

Biomy makes DeepPathFinder, cloud software that uses AI to map immune and cancer cells on tissue slides for drug research.

Imagene AI reads routine stained lung cancer slides and predicts which gene changes a tumor carries, without using more tissue for sequencing.

Bioptimus is a Paris company that builds AI foundation models for pathology and biology. Drug companies, research groups and pathology software makers license them as a base for their own tools.

Lunit SCOPE is the pathology AI line of Lunit, the Seoul medical AI company. Drug companies, contract research organizations and digital pathology platforms use it to measure cancer biomarkers on tissue slides for research and trials.

Aiosyn sells AI that analyzes images of stained tissue, to pathology laboratories and to drug companies running animal studies.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published
Research use virtual staining software (ClearStain, DeepStain, ReStain, RetroStain) and the Tissue Intelligence Platform, deployed on an appliance in the customer's network or in a Pictor Labs managed cloud; no unit of charge or price published. Not published. The privacy policy covers website and account data; no business associate or data processing agreement is published. Not published. Vendor Published

PictorLabs describes its four staining products and its Tissue Intelligence Platform, their inputs and outputs, and the two deployment options, with a biomarker menu on request and access through a demo request. Nothing says whether customers pay per slide, per stain, per study or by license.

PictorLabs pricing in full →